Essen, Germany. Evonik has invested €25 million developing and expanding its methylmercapto-propionaldehyde (MMP) production plant in Wesseling, Germany, in the latest move to strengthen its world-scale global methionine production network.
MMP is integral in the production of MetAMINO® (DL-methionine) which is used in animal feed to improve the performance of livestock farming. The precursors of this essential amino acid have been produced in Wesseling for more than 50 years.
Dr. Gaetano Blanda, head of Animal Nutrition business line, said: "With this investment, Evonik is strengthening the European methionine network to safeguard the long-term supply of MMP to our MetAMINO® production hub in Antwerp, Belgium. The move underscores our commitment to serving and expanding the global DL-methionine market and secures the best possible supply security for our customers.”
The conversion and expansion of the plant in Wesseling has been made possible by the development of a new production process, that will allow to avoid the storage of chemical intermediates, such as acrolein, at the site.
Commenting on the plant upgrade, Dr. Jan-Olaf Barth, head of the Essential Nutrition product line, said: “Evonik is known for its innovative approach and world-class technology, and in Wesseling we have now developed a process that increases efficiency and, with Responsible Care in mind, further enhances safety at the site."
He added: “This investment is a building block of our global methionine asset strategy with the clear goal of being the cost and technology leader in all regions, and the reliable partner for our customers.”
At the heart of Evonik’s methionine asset strategy are three world-class global production hubs covering Europe (Antwerp, Belgium), Asia (Singapore) and the Americas (Mobile, Alabama).
Consolidating production at these hubs ensures a reliable product supply as well as offering opportunities for cost-efficient debottlenecking and future expansion.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.56 billion in 2021 with about 5,300 employees.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.